文献速递药物不良反应与药物警戒

重新评估非佐奈坦的肿瘤信号:监管推断、机制合理性及主动药物警戒的必要性

Reassessing the Neoplasm Signal with Fezolinetant: Regulatory Inference, Mechanistic Plausibility, and the Case for Proactive Pharmacovigilance.
PubMed 文献 · Drug Saf · 2026-10-14

非佐奈坦是首个获批用于绝经相关中重度血管舒缩症状的NK3R拮抗剂,其肿瘤信号尚未明确。作者从暴露调整发病率、监管文献引用及机制合理性三方面重新评估,认为该信号呈剂量相关但未达统计学显著,现有机制论证不充分,建议加强上市后监测与独立安全性审查。

要点

  • 非良性肿瘤暴露调整发病率随安慰剂、30mg、45mg递增,分别为0.2、0.7、1.2/100受试年。
  • 获批剂量下相对风险6.6(95%CI 0.9-51.3),按13个器官类条目重算为7.83,呈剂量相关但无统计学显著性。
  • 欧洲监管文献综述所引15篇参考文献中11篇涉及NK1R而非NK3R,机制外推不成立。

核心结论

  • 非佐奈坦的肿瘤信号呈剂量相关但未达统计学显著,现有监管推断与机制论证存在不足。
  • 建议开展结构化上市后监测、定期独立安全性审查并重新审视机制合理性。

研究设计与样本

  • 本文为对非佐奈坦肿瘤信号的重新评估,基于SKYLIGHT III期项目数据及欧洲监管文献综述。

主要发现

  • 非良性肿瘤暴露调整发病率在安慰剂、30mg和45mg组分别为0.2、0.7和1.2/100受试年。
  • 获批剂量下相对风险为6.6(95%CI 0.9-51.3),按13个器官类条目重算为7.83。
  • 欧洲监管文献综述所引15篇参考文献中,11篇涉及NK1R或P物质而非NK3R,2篇仅报告NK3R在口腔鳞癌中的表达而未给药,1篇无肿瘤数据,仅1篇给予NK3R拮抗剂并发现减轻肿瘤负荷。

临床怎么用

  • 临床使用非佐奈坦时应关注肿瘤相关不良事件,并配合上市后结构化监测。

局限性

  • 肿瘤事件不平衡未达统计学显著,机制论证基于间接证据,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fezolinetant, the first neurokinin-3 receptor (NK3R) antagonist licensed for moderate-to-severe vasomotor symptoms associated with menopause, carries an unresolved neoplasm signal. An imbalance in neoplasm events across the SKYLIGHT phase III programme, raised in 2023, has been set aside by regulators as a chance finding lacking a plausible mechanism. We reassess that inference on three grounds. First, exposure-adjusted incidence of non-benign neoplasms rises across placebo, 30 mg and 45 mg, at 0.2, 0.7 and 1.2 per 100 subject-years, giving a relative risk at the licensed dose of 6.6 (95% confidence interval 0.9-51.3); a published recalculation gives 7.83 by counting 13 organ-class entries rather than 11 affected participants. The imbalance is dose related but not statistically significant. Second, of the 15 references mobilised in the European regulatory literature review to support that position, 11 concern the neurokinin-1 receptor or substance P rather than NK3R, two report NK3R expression in oral squamous cell carcinoma without administering an antagonist, one contains no neoplasm data and one alone administers an NK3R antagonist, finding that it reduced tumour burden. The pharmacology of the two receptors does not permit the extrapolation. Third, four mechanisms merit evaluation: loss of KISS1-mediated metastasis suppression and dormancy control, compensatory neurokinin-1 receptor activation by unbound neurokinin B, loss of anti-angiogenic restraint and acceleration of lesions already present. None requires de novo carcinogenesis, so the short-latency argument is not decisive. We recommend structured post-authorisation surveillance, a periodic independent safety review and re-examination of the mechanistic rationale.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Clack G, Renwick J. Reassessing the Neoplasm Signal with Fezolinetant: Regulatory Inference, Mechanistic Plausibility, and the Case for Proactive Pharmacovigilance. Drug Saf. 2026. PMID: 42873405. doi:10.1007/s40264-026-01737-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。